(Finance) – The Board of Directors of Svas Biosanaa leading operator in the healthcare sector listed on Euronext Growth Milan, has approved the issuance of a non-convertible and non-subordinated bond loan of a nominal amount equal to 6 million euros.
The issuance of the Loan, which represents a concrete alternative and complementary instrument for the Company to traditional bank financing, is indicatively expected by November 2024.
The Loan will be in full offered for subscription to a securitization vehicle within the scope of a basketball bond in which Banca Finint has the role of senior investor will have the following characteristics: issued in a single tranche; issue price equal to 100% of the nominal value; duration of approximately six years and six months starting from the date of issue and expiring in May 2031.
The bond will not be subject to listing on regulated markets or admitted to trading on a multilateral trading system and will be issued exempt from the obligation to publish an offering prospectus.